| Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10269), 99-111, 2021 | 5713 | 2021 |
| Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial PM Folegatti, KJ Ewer, PK Aley, B Angus, S Becker, ... The Lancet 396 (10249), 467-478, 2020 | 2939 | 2020 |
| Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial MN Ramasamy, AM Minassian, KJ Ewer, AL Flaxman, PM Folegatti, ... The Lancet 396 (10267), 1979-1993, 2020 | 1763 | 2020 |
| Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four … M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet, 2021 | 1415 | 2021 |
| Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 VOC 202012/01 (B. 1.1. 7) KRW Emary, T Golubchik, PK Aley, CV Ariani, BJ Angus, S Bibi, B Blane, ... | 766* | 2021 |
| T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial KJ Ewer, JR Barrett, S Belij-Rammerstorfer, H Sharpe, R Makinson, ... Nature Medicine, 1-9, 2020 | 629 | 2020 |
| Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses JR Barrett, S Belij-Rammerstorfer, C Dold, KJ Ewer, PM Folegatti, ... Nature medicine 27 (2), 279-288, 2021 | 356 | 2021 |
| The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody AD Douglas, AR Williams, JJ Illingworth, G Kamuyu, S Biswas, ... Nature communications 2 (1), 1-9, 2011 | 328 | 2011 |
| The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody. Nat Commun 2: 601 AD Douglas, AR Williams, JJ Illingworth, G Kamuyu, S Biswas, ... doi. org/10.1038/ncomms1615, 2011 | 328* | 2011 |
| Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002) A Flaxman, NG Marchevsky, D Jenkin, J Aboagye, PK Aley, B Angus, ... The Lancet 398 (10304), 981-990, 2021 | 285 | 2021 |
| A PfRH5-Based Vaccine Is Efficacious against Heterologous Strain Blood-Stage Plasmodium falciparum Infection in Aotus Monkeys AD Douglas, GC Baldeviano, CM Lucas, LA Lugo-Roman, C Crosnier, ... Cell Host & Microbe 17 (1), 130-139, 2015 | 268 | 2015 |
| ChAd63-MVA–vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans SH Sheehy, CJA Duncan, SC Elias, P Choudhary, S Biswas, FD Halstead, ... Molecular Therapy 20 (12), 2355-2368, 2012 | 263 | 2012 |
| Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial J Frater, KJ Ewer, A Ogbe, M Pace, S Adele, E Adland, J Alagaratnam, ... The Lancet HIV, 2021 | 248 | 2021 |
| Structure of malaria invasion protein RH5 with erythrocyte basigin and blocking antibodies KE Wright, KA Hjerrild, J Bartlett, AD Douglas, J Jin, RE Brown, ... Nature 515 (7527), 427-430, 2014 | 233 | 2014 |
| Neutralization of Plasmodium falciparum Merozoites by Antibodies against PfRH5 AD Douglas, AR Williams, E Knuepfer, JJ Illingworth, JM Furze, ... The Journal of Immunology 192 (1), 245-258, 2014 | 178 | 2014 |
| Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults C Ogwang, D Kimani, NJ Edwards, R Roberts, J Mwacharo, G Bowyer, ... Science translational medicine 7 (286), 286re5-286re5, 2015 | 173 | 2015 |
| Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals SH Hodgson, KJ Ewer, CM Bliss, NJ Edwards, T Rampling, ... The Journal of infectious diseases 211 (7), 1076-1086, 2014 | 169 | 2014 |
| Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions RO Payne, SE Silk, SC Elias, K Miura, A Diouf, F Galaway, H de Graaf, ... JCI insight 2 (21), 2017 | 160 | 2017 |
| Enhancing blockade of Plasmodium falciparum erythrocyte invasion: assessing combinations of antibodies against PfRH5 and other merozoite antigens AR Williams, AD Douglas, K Miura, JJ Illingworth, P Choudhary, ... PLoS Pathog 8 (11), e1002991, 2012 | 153 | 2012 |
| Human antibodies that slow erythrocyte invasion potentiate malaria-neutralizing antibodies DGW Alanine, D Quinkert, R Kumarasingha, S Mehmood, FR Donnellan, ... Cell 178 (1), 216-228. e21, 2019 | 149 | 2019 |
Simon J DraperProfessor of Vaccinology and Translational Medicine, University of OxfordEmail được xác minh tại paediatrics.ox.ac.uk
